Introduction {#section1-1533033818821104}
============

Sentinel lymph node (SLN) biopsy has become the gold standard for staging of axillary lymph node status in patients with breast cancer (BC). It is recognized that SLN biopsy can predict axillary lymph nodes status accurately.^[@bibr1-1533033818821104][@bibr2-1533033818821104][@bibr3-1533033818821104]-[@bibr4-1533033818821104]^ In the neoadjuvant therapy (NAT) setting, intraoperative SLN assessment is less established but is increasingly being utilized in favor of axillary lymph node dissection (ALND).^[@bibr5-1533033818821104]^ Intraoperative assessment of SLN biopsy in patients with BC post-NAT is beneficial because a positive finding results in an immediate axillary node dissection and avoids a separate subsequent completion ALND. As well, the post-NAT lymph node has the potential to have complete response to therapy, be downstaged, and subsequently patients with positive axillary lymph node pre-NAT may be spared from the morbidity of ALND. However, frozen section (FS) SLN post-NAT may demonstrate tumor bed changes and may have scant or focal residual carcinoma, making intraoperative analysis challenging.^[@bibr6-1533033818821104]^

A few studies have examined the accuracy of FS SLN analysis post-NAT, with false-negative rates (FNRs) ranging from 20% to 26.2%.^[@bibr7-1533033818821104][@bibr8-1533033818821104][@bibr9-1533033818821104]-[@bibr10-1533033818821104]^ These studies, however, lacked detailed analysis of pathological, radiological, and clinical parameters that may predict discordance between intraoperative assessment and final diagnosis. We studied the accuracy of intraoperative assessment of SLN biopsies after NAT in 2 institutions. Further, we identified clinical, radiological, and pathological parameters that may predict an increased risk of false-negative SLN intraoperative assessment.

Materials and Methods {#section2-1533033818821104}
=====================

Approval for this study was obtained from the ethics committees of the participating institutions. The data used for these analyses were collected between January 1, 2010, and December 31, 2015, for Sunnybrook Health Sciences Center and between March 2015 and November 2016 for North York General Hospital.

Eligibility Criteria {#section3-1533033818821104}
--------------------

We included patients (1) with biopsy confirmed primary invasive BC, (2) had completed neoadjuvant chemotherapy (the regimen was at the discretion of the medical oncologist), (3) continued on to have primary resection of tumor and axillary lymph node sampling, and (4) with slides from the intraoperative and permanent specimens available for review. In total, 49 NAT patients from Sunnybrook Health Sciences Center, a tertiary cancer center, and 28 NAT patients from North York General Hospital, a community hospital, were studied. This was compared to 88 patients with BC from the non-NAT setting treated at Sunnybrook Health Sciences Center.

Sentinel Lymph Node Evaluation {#section4-1533033818821104}
------------------------------

Sentinel lymph node surgery incorporated injection of tracer to determine lymphatic drainage pathway. A combination of radiolabeled colloid and blue dye was used as tracer. The first lymph node(s) along the drainage pathway was identified by the tracer and the SLN biopsied. Intraoperatively, each SLN was sectioned into 2- to 3-mm thick cross-sections and submitted in toto. Each SLN was examined with at least 1 section stained with hematoxylin and eosin (H&E), and, if necessary, additional H&E sections were performed. After the intraoperative consultation, the SLN specimen was resubmitted in toto for permanent sections after formalin fixation. At least 1 H&E stained permanent section and one permanent section stained with CK8/18 immunostain were examined for each SLN. Positive SLNs were defined as those with any metastatic cells including isolated tumor cells (ITCs).

Analysis {#section5-1533033818821104}
--------

Clinical, radiological, and pathological features were obtained from the electronic patient record and pathology database for all patients in the NAT and non-NAT setting. Univariate analysis was performed using 2-tailed Student *t* test to identify statistically significant differences between means, and Fisher exact test was used for categorical variables. *P* values of \<.05 were considered statistically significant. All slides of cases with discordance between FS and permanent sections were retrieved in order to histologically evaluate the nature of the discrepancy.

Results {#section6-1533033818821104}
=======

All discordant cases in non-NAT and NAT patients were false negatives, and there were no false positives. Combining results from both institutions, SLNs were correctly assessed with FS in 68 of 77 NAT patients. Sensitivity, specificity, and accuracy were 71.9%, 100%, and 88.3%, respectively ([Table 1](#table1-1533033818821104){ref-type="table"}). False-negative rate in NAT patients was 28.1%. The cancer center and community hospital were similar in terms of sensitivity, specificity, and accuracy. Sensitivity, specificity, and accuracy were 68.8%, 100%, and 89.8%, respectively, at the cancer center and 75%, 100%, and 85.7% at the community hospital. In the non-NAT patients from the cancer center, 72 of 88 metastatic cases were identified correctly and sensitivity, specificity, and accuracy were 50%, 100%, and 81.8%, respectively. Finally, FNR in non-NAT patients was 50%.

###### 

Diagnostic Parameters of Intraoperative Analysis of Sentinel Lymph Nodes.

![](10.1177_1533033818821104-table1)

                      Sensitivity   Specificity   PPV   NPV    Accuracy   FNR
  ------------------- ------------- ------------- ----- ------ ---------- ------
  NAT patients                                                            
   ITC included       71.9          100           100   83.3   88.3       28.1
   ITC not included   79.3          100           100   88.2   91.9       20.7
  Non-NAT patients                                                        
   ITC included       50            100           100   77.8   81.8       50
   ITC not included   66.7          100           100   87.5   90         33.3

Abbreviations: FNR, false-negative rate; ITC, isolated tumor cell; NAT, neoadjuvant; NPV, negative predictive value; PPV, positive predictive value.

Clinical, radiological, and pathological features of the total population of both NAT and non-NAT patient groups are presented in [Table 2](#table2-1533033818821104){ref-type="table"}. In univariate analysis of clinicopathological features in NAT patients, an Estrogen Receptor (ER)-positive and HER2-negative breast biomarker profile and SLN metastasis that were ITCs or micrometastasis were identified as risk factors associated with discordant results between intraoperative and permanent sections. In non-NAT cases, a larger (T2 or T3) radiological size of the primary BC, SLN metastasis that were ITCs or micrometastasis, and BC with a lobular histologic subtype predicted discordance. In general, results from the NAT patients between the cancer center and community hospital were comparable (results not shown).

###### 

Patient and Tumor Characteristics.

![](10.1177_1533033818821104-table2)

                                     NAT Patients   Non-NAT Patients                      
  ---------------------------------- -------------- ------------------ ------ ----- ----- --------
  Number of patients                 68             9                         72    16    
  Average age at diagnosis (years)   50.5           48.3               .961   58    61    .380
  Average number of SLN on FS        3.264          4.11               .119   3.1   3.4   .302
  Lymph node cytology                                                                     
   Positive                          11             0                  .258   0     0     1.000
   Negative                          14             3                  14     4           
   Not done                          43             6                  57     14          
  Radiologic tumor size, mm                                                               
   ≤20                               14             1                  .230   46    5     .027
   \>20 to ≤50                       40             4                  15     8           
   \>50                              11             4                  9      2           
   Not available                     3              0                  2      1           
  Histologic type                                                                         
   IDC                               61             7                  .374   61    11    .022
   ILC                               2              0                  5      5           
   Other                             5              2                  6      0           
  Type of LN metastasis                                                                   
   No metastasis                     45             0                  .004   56    0     \<.001
   ITC                               0              3                  0      8           
   Micromet                          3              2                  2      6           
   Macromet                          20             4                  14     2           
  Biomarker                                                                               
   ER(+), HER2(+)                    13             0                  .022   8     3     .404
   ER(+), HER2(−)                    21             8                  50     12          
   ER(−), HER2(+)                    5              0                  4      0           
   ER(−), HER2(−)                    28             1                  8      0           
   ER(+), HER2(equiv)                0              0                  1      1           
   ER(−), HER2(equiv)                0              0                  1      0           
  Nuclear grade                                                                           
   1                                 1              0                  .187   13    1     .311
   2                                 13             0                  34     11          
   3                                 31             9                  24     4           
   Not graded                        23             0                  1      0           
  Radiologic response                                                                     
   No response                       1              1                  .401               
   Partial response                  11             2                                     
   Marked response                   7              0                                     
   Complete response                 4              0                                     
   No comment                        45             6                                     

Abbreviations: Equiv, equivocal; FS, frozen section; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ITC, isolated tumor cell; LN, lymph node; Macromet, macrometastasis; Micromet, micrometastasis; NAT, neoadjuvant; *P*, *P* value; SLN, sentinel lymph node; +, positive; −, negative.

The nature of discordances in the NAT patients was separated into sampling-type errors and interpretative-type errors. Sampling-type errors are encountered when the metastatic deposits are not seen on FS but identified on the deeper levels of permanent sections or immunohistochemistry. Interpretative-type errors are metastases present on FS but missed intraoperatively. Of the 9 discordant cases, 7 cases were sampling-type errors only, and 2 cases were both sampling- and interpretative-type errors. [Figures 1](#fig1-1533033818821104){ref-type="fig"} and [2](#fig2-1533033818821104){ref-type="fig"} are FS slide images of the 2 discordant cases with interpretative-type errors. In both cases, missed metastasis was associated with tumor bed changes. In terms of outcome, 4 of the 9 false-negative diagnoses went on to have ALND in a subsequent surgery.

![Case 1 demonstrates a focus of isolated tumor cells measuring 0.15 mm that was missed intraoperatively due to its minute size.](10.1177_1533033818821104-fig1){#fig1-1533033818821104}

![Case 2 demonstrates a focus of macrometastasis measuring 6 mm that was missed intraoperatively due to its lobular growth pattern.](10.1177_1533033818821104-fig2){#fig2-1533033818821104}

Discussion {#section7-1533033818821104}
==========

Lymph node status is one of the most important prognosticators in BC.^[@bibr11-1533033818821104]^ Axillary lymph node dissection was originally the standard management to assess nodal status; however, it is associated with high morbidity. Sentinel lymph node biopsy followed by adjuvant radiotherapy in early-stage and limited SLN metastatic disease is the current standard of management in the non-NAT setting.^[@bibr12-1533033818821104]^ The American Society of Clinical Oncology recently recommended SLN biopsy for NAT patients based on the benefits of avoidance of ALND morbidity and the potential of lymph node downstage following NAT; however, guidelines in the literature on intraoperative assessment of BC in the NAT setting are not well established.^[@bibr12-1533033818821104]^

For non-NAT patients, recent studies have demonstrated that FNR for intraoperative assessment of SLN vary from 13% to 22.6%,^[@bibr13-1533033818821104][@bibr14-1533033818821104][@bibr15-1533033818821104][@bibr16-1533033818821104]-[@bibr17-1533033818821104]^ including cases with ITCs. Meanwhile for NAT patients, approximately 50% of patients have residual nodal disease after NAT,^[@bibr18-1533033818821104]^ and FNR for intraoperative assessment vary from 20% to 26.1%,^[@bibr7-1533033818821104][@bibr8-1533033818821104][@bibr9-1533033818821104]-[@bibr10-1533033818821104]^ including cases with ITCs. In our multi-institutional study, when ITCs are included in the analyses FNR for non-NAT and NAT are 50% and 28.1%, respectively. When ITCs are omitted from our analyses, FNR improves significantly, with FNR for non-NAT and NAT being 33.3% and 20.7%, respectively. The relationship of ITCs and discordance has been described in the literature on intraoperative SLN assessment.^[@bibr7-1533033818821104][@bibr8-1533033818821104][@bibr9-1533033818821104]-[@bibr10-1533033818821104],[@bibr13-1533033818821104][@bibr14-1533033818821104][@bibr15-1533033818821104][@bibr16-1533033818821104][@bibr17-1533033818821104]-[@bibr18-1533033818821104]^ In the non-NAT patients, we found higher number of cases with ITCs present than in the NAT patients, and this affected the overall sensitivity and accuracy. The lower number of cases with ITCs present in NAT patients may represent the effectiveness of systemic therapy in eliminating ITCs. There is importance in identifying ITCs in NAT patients, as it may predict an aggressive population of chemoresistant cells either originating from macroscopic nodal metastasis that has undergone partial response or minimal nodal disease that did not respond to NAT.^[@bibr19-1533033818821104],[@bibr20-1533033818821104]^ The accuracy of the intraoperative SLN assessment in NAT patients between community hospital and cancer center was quite comparable. This suggests that FS assessment of NAT SLN can be accurately carried out at both community and cancer centers.

To our knowledge, our study is the first study to analyze in detail clinical, radiological, and pathological features that may predict discordant results in intraoperative FS assessment in both NAT and non-NAT patients. In our study, smaller size of SLN metastasis was associated with false negatives in both NAT and non-NAT patients. Biomarker profile determined on core needle biopsy also demonstrated association with discordance in NAT patients. Of the 9 NAT cases with discordant intraoperative SLN assessment, 8 cases had a biomarker profile of ER-positive and HER2-negative immunophenotype. One case had ER-negative and HER2-negative immunophenotype and had a sampling-type error, where the lesional cells were only identified on deeper sectioning. The propensity for ER-positive and HER2-negative immunophenotype to have discordance can be explained by this biomarker profile's relative resistance to systemic therapy, and thus the tendency to have lymph node metastases refractory to treatment.^[@bibr21-1533033818821104][@bibr22-1533033818821104]-[@bibr23-1533033818821104]^ In non-NAT patients, larger radiologic tumor size (T2 or T3) and lobular histotype also significantly predicted false negatives; these findings were not seen in NAT patients. Clinical and radiologic tumor size have been shown to be associated with increased risk of lymph node metastasis, and metastatic carcinoma with lobular histotype is notoriously difficult to identify in an intraoperative setting due to its propensity to grow as single cells and its low nuclear grade.^[@bibr24-1533033818821104],[@bibr25-1533033818821104]^

Among the 9 discordant NAT cases, all cases had sampling-type errors and 2 cases had interpretative-type errors as well. FS artifacts such as tissue folding and tissue shattering of adipocytic lymph nodes accounted for some of the sampling-type errors. In addition, some metastases were revealed in deeper sections. Missed metastatic deposits were typically found in areas with tumor bed change consisting of fibrosis, lymphohistiocytic inflammatory infiltrate, and loss of normal lymph node architecture. Good quality FS and careful microscopic examination of the lymph node during intraoperative assessment, especially in areas with tumor bed changes, are essential to limit FNRs due to both sampling- and interpretative-type errors.

It is important to limit false negatives as 4 of the 9 discordant NAT cases went on to have ALND in a subsequent surgical procedure. In terms of outcomes, the need for ALND versus axillary radiotherapy in women with residual metastatic lymph node disease is being examined in the Alliance A011202 trial.^[@bibr26-1533033818821104],[@bibr27-1533033818821104]^ Recurrence-free period, overall survival, and side effects are also to be studied. While awaiting the results for this trial, the clinical decision for ALND following a false-negative SLN diagnosis varies and often requires a multidisciplinary decision.

Our study has several limitations. Our study is a retrospective nonrandomized study. Therefore, the patient and tumor characteristics of cases treated with and without NAT were different, with the NAT group having younger age at diagnosis, more positive lymph node cytology, larger radiologic tumor size, more ER-negative and HER-positive biomarker profiles, and higher nuclear grade. As ALND post-NAT is still the current standard of treatment for patients with positive LN pre-NAT, with SLN biopsy performed in such patients only starting 2010, our sample size is small.

Conclusion {#section8-1533033818821104}
==========

Detection of SLN metastases by intraoperative FS assessment post-NAT is feasible and demonstrates similar results as in non-NAT setting, although FNR are high in both settings especially with the inclusion of ITCs. Discordance in NAT cases showed statistically significant association with ER-positive/HER2-negative biomarker profile and size of metastatic deposit. The FS SLN biopsy in the community and academic setting shows similar sensitivity, specificity, and accuracy as well as clinicopathological parameters that may predict discordance. Careful examination of lymph nodes and awareness of characteristics that may predict discordance is necessary to avoid high FNR.
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ALND

:   axillary lymph node dissection

BC

:   breast cancer

FNR

:   false-negative rates

FS

:   frozen section

H&E

:   hematoxylin and eosin

ITC

:   isolated tumor cells

NAT

:   neoadjuvant therapy

SLN

:   sentinel lymph node.

ER

:   Estrogen Receptor.
